DEF: Akebia Therapeutics Seeks Stockholder Approval for Amended Stock Incentive Plan

Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance and make other changes.

Summary

• Akebia Therapeutics is seeking stockholder approval to amend its 2023 Stock Incentive Plan.
• The proposed amendment includes increasing the number of shares available for issuance by 18,900,000, preventing shares used for option exercise or tax withholding from returning to the plan, and adding minimum vesting provisions.
• If approved, the new shares would represent approximately 7.22% of the company's outstanding shares as of March 31, 2025.
• The company intends to use the amended plan to grant equity awards to employees, non-employee directors, consultants, and advisors.
• The Board of Directors believes the amendment is crucial for retaining and incentivizing talented employees in a competitive environment.
• As of March 31, 2025, the company had 18,466,697 outstanding stock options with a weighted average exercise price of $3.09 and 7,108,175 outstanding RSUs.
• The company's overhang as of March 31, 2025, was 11.8%, which would increase to 19.1% if the amendment is approved.
• The average burn rate for the past three years (2022-2024) was 4.63%.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the details of the proposed amendment to the stock incentive plan. The sentiment is neutral, with a slight positive leaning due to the company's belief that the amendment is crucial for its future success.

Positives

• The amended plan includes features to protect stockholder interests, such as no evergreen provision, a clawback policy, and no repricing of awards.
• Equity-based compensation aligns employee and director interests with stockholder interests.
• The company's overhang is low relative to its peer group.
• The proposed share pool is expected to allow the company to continue granting equity awards for approximately two years.

Negatives

• Approval of the amendment will increase the company's overhang from 11.8% to 19.1%.
• If the amendment is not approved, the company may need to increase cash compensation, reducing resources for business needs.

Risks

• If the amendment is not approved, the company may face challenges in attracting and retaining talent.
• The inability to make market-based equity awards could negatively impact the business.
• A significant portion of outstanding stock options have an exercise price greater than the current stock price, reducing their effectiveness as incentives.

Future Outlook

The company expects the proposed share pool under the Amended Plan will allow it to continue to grant equity awards at its historic rates for approximately two years.

Industry Context

The document mentions that the company's compensation practices are consistent with those of other pharmaceutical companies in its peer group and other companies that it competes with for talent.

Comparison to Industry Standards

• The document compares Akebia's potential shareholder dilution and overhang to its peer group, indicating that its potential shareholder dilution was 10.2% compared to a 50th percentile of 14.8%, and its overhang was 11.8% as compared to a 50th percentile of 21.6%.
• The document also compares Akebia's burn rate to its peer group, stating that its 2024 equity usage was 4.4%, which was below the 25th percentile as compared to its peer group.

Stakeholder Impact

• Approval of the amendment could impact stakeholders by allowing the company to better attract and retain talent, potentially leading to improved performance.
• Stockholders may experience dilution if the amendment is approved.
• Employees may benefit from continued equity-based compensation opportunities.

Next Steps

• Stockholder vote on the proposed amendment at the 2025 Annual Meeting.
• If approved, the company intends to register the additional shares by filing a Registration Statement on Form S-8.

Key Dates

Keywords

stock incentive plan, equity compensation, share authorization, overhang, burn rate, executive compensation, stock options, RSUs, Akebia Therapeutics